Apricus Licenses Its Own Drug Back From Allergan
This article was originally published in Scrip
Apricus Biosciences successfully confused its investors on Sept. 10 when the San Diego-based company announced that it managed to license its own topical treatment for erectile dysfunction (ED) from Allergan for a meager $1m upfront payment plus a future $1.5m regulatory milestone fee.
You may also be interested in...
After feedback on a very old complete response, biotech plans to resubmit a filing in the second half of 2017, instead of the fourth quarter, and will need to engage the Office of Product Quality because Vitaros is viewed as a drug/device combination.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.